A serious adverse event may be documented at a trial site, reviewed by the clinical team, and passed to pharmacovigilance staff for assessment. Each handover is a point where information can go missing, be delayed, or be recorded inconsistently.

This post is for sponsors, CROs, and clinical operations and drug safety teams. It looks at how GCP in pharmacovigilance works in practice, four places where safety reporting commonly breaks down, and what you can review now without adding new procedures. 

How GCP in Pharmacovigilance Divides the Work

GCP defines the rules governing the conduct of trials, involving aspects such as investigator duties, documentation, oversight, and safety reporting. These requirements are also central to effective GCP audits. Pharmacovigilance deals with the detection, assessment, and prevention of adverse events and other safety issues related to medicines. These are two different activities that complement each other. An adverse event detected at the trial site may need medical assessment, additional information, expedited reporting, or updating the risk assessment of the trial. When roles are not clearly defined, the whole process is disrupted.

Four Points Where Safety Reporting Breaks Down

Delayed communication

Investigators must report serious adverse events to the sponsor promptly, within the timelines set by applicable requirements and the protocol. Delays affect medical review, follow-up, and regulatory reporting.

Incomplete safety documentation

Missing event dates, medical histories, laboratory results, or treatment details make assessment difficult. Each missing item generates a query, which adds work for investigators and pharmacovigilance teams.

Mismatched records

When source documents, clinical databases, and safety databases disagree, the reliability of the data is questioned. Regular reconciliation finds these differences before they become compliance findings.

Unclear ownership

Sponsors can outsource pharmacovigilance activities, but they remain responsible for oversight. Without defined roles and escalation paths, safety cases can move between teams without anyone clearly owning them.

What Sponsors Can Review Now

There is no need for sponsors to create additional procedures to ensure effective reporting of safety information. It is essential to examine how the current procedures function. Examples of such reviews include assessing adverse event reporting duties and escalation procedures, reconciling clinical and safety databases consistently, following up on the reporting times and open queries, as well as reviewing deviations from safety-related procedures and their corrective measures.

A GCP-independent audit helps to assess how the described processes are implemented in reality. The audit reveals differences between the procedure and its actual implementation. For a closer look at common sponsor oversight gaps, read our article on GCP compliance gaps sponsors often miss.

Pharmazone’s pharmacovigilance team helps sponsors and CROs review safety reporting workflows, identify gaps, and strengthen oversight. Learn more about our pharmacovigilance services.

Frequently Asked Questions

What is the difference between GCP and GVP?
GCP governs how clinical trials are conducted and how trial participants are protected. Good Pharmacovigilance Practices (GVP) guide safety monitoring of authorized medicines, mainly after approval. In a trial, the two overlap wherever safety information is collected and reported.

Who is responsible for SAE reporting in a clinical trial?
The investigator reports SAEs to the sponsor. The sponsor is responsible for assessing them and for expedited reporting to regulators and ethics committees, even if tasks are delegated to a CRO.

What is safety database reconciliation?
It is the comparison of adverse event data between the clinical database and the safety database to identify and resolve discrepancies in dates, terms, seriousness, or outcomes.

How Pharmazone Can Help
Pharmazone’s pharmacovigilance team helps sponsors and CROs review safety reporting workflows, identify gaps, and strengthen oversight.

Conclusion

GCP in pharmacovigilance is about making sure safety information is accurate, traceable, and available when clinical decisions depend on it. Sponsors that integrate GCP oversight into their pharmacovigilance processes are better positioned to protect participants and maintain confidence in their trial data.

Speak with Pharmazone’s team about your trial safety processes.